BUSULFAN+ FLUDARABİN(AZALTILMIŞ YOĞUNLUKLU)(RIC)

Kaynaklar:

1-Kroger, N., S. Iacobelli, G. N. Franke, et al. 2017. "Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)." J Clin Oncol 35(19):2157-2164.

2-Rubio, M. T., M. D'Aveni-Piney, M. Labopin, et al. 2017. "Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party." J Hematol Oncol 10(1):31.

3-Bhurani, D., M. Schifter and I. Kerridge. 2008. "Folinic acid administration following MTX as prophylaxis for GVHD in allogeneic HSCT centres in Australia and New Zealand." Bone Marrow Transplant 42(8):547-550.

4-Ma, S., W. Shi, Z. Li, et al. 2020. "Reduced-intensity versus Myeloablative Conditioning Regimens for Younger Adults with Acute Myeloid Leukemia and Myelodysplastic Syndrome: A systematic review and meta-analysis." J Cancer 11(17):5223-5235.

5-Jain, T., F. Alahdab, B. Firwana, et al. 2019. "Choosing a Reduced-Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation, Fludarabine/Busulfan versus Fludarabine Melphalan: A Systematic Review and Meta-Analysis." Biol Blood Marrow Transplant 25(4):728-733.